Please ensure Javascript is enabled for purposes of website accessibility

FDA Authorizes Coronavirus Tests in Academic Laboratories Across U.S.

By Mark Prvulovic - Updated Apr 6, 2020 at 8:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Health authorities are letting more organizations do tests of their own.

The U.S. Food and Drug Administration (FDA) announced on Saturday that it will now allow academic hospital labs across the country to begin testing for COVID-19, with the agency estimating that around 300 to 400 medical centers will be able to start effective immediately.

Before this announcement, the U.S. government's testing capabilities had been relatively limited, with only the Centers for Disease Control and Prevention (CDC) having developed an official test for COVID-19. However, the results have proved to be somewhat unreliable, something which has prompted other groups to try to develop their own tests.

A nurse holding a coronavirus test in her hand.

Image source: Getty Images.

"We believe this policy strikes the right balance during this public-health emergency," said FDA Commissioner Stephen M. Hahn. "We will continue to help to ensure sound science prior to clinical testing and follow-up with the critical independent review from the FDA, while quickly expanding testing capabilities in the U.S." 

Further details

The announcement follows an earlier news conference in which President Trump warned the American public and the press to remain calm as the first U.S. coronavirus death was officially confirmed, involving a Washington state man in his 50s. Health officials along the West Coast are worried that further outbreaks are possible, especially since the woman who died didn't contract COVID-19 from travelling abroad.

Moderna (MRNA -5.06%) and Gilead Sciences (GILD -1.27%) are two biotech stocks developing potential COVID-19 treatments right now. Gilead is using its former Ebola drug, remdesivir, while Moderna has developed a new mRNA-based vaccine. Both treatments have begun human clinical trials.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$150.00 (-5.06%) $-8.00
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$65.18 (-1.27%) $0.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.